Physician profile
Patrick H Platzer
NPI 1790282465
$4,681.55
in general payments reported to CMS, 2019-2025
30 companies · $752 in 2025
The $752 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.53 · 2022: $1,314 · 2023: $1,074 · 2024: $1,526 · 2025: $752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,351.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $792.17 | 2022-2025 | Watchman Access System, Watchman Flx |
| Abbott Laboratories | $405.83 | 2024-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Aveir, Cardiomems |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $404.92 | 2021-2025 | Lifevest |
| Shockwave Medical, INC | $306.15 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Cvrx, INC. | $239.98 | 2024 | Barostim Neo System |
| Pfizer INC. | $217.44 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.47 | 2022-2023 | Jardiance |
| Astellas Pharma US INC | $198.00 | 2022 | |
| Atricure, INC. | $194.30 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $173.60 | 2022-2024 | Camzyos, Eliquis |
| Abiomed | $165.18 | 2024 | Impella |
| Inari Medical, INC. | $159.45 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Amgen INC. | $150.48 | 2022-2025 | Repatha, Repatha |
| Medtronic, INC. | $136.47 | 2023 | Linq II, Cobalt Dr Mri Surescan |
| Edwards Lifesciences Corporation | $135.00 | 2023-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $119.43 | 2024-2025 | Opsumit, Uptravi, Opsynvi |
| Lantheus Medical Imaging, INC. | $82.00 | 2023-2025 | Definity |
| Kiniksa Pharmaceuticals International, Plc | $71.60 | 2024 | Arcalyst |
| Inspire Medical Systems, INC. | $67.45 | 2024-2025 | Inspire |
| Alnylam Pharmaceuticals INC. | $65.02 | 2022-2025 | Amvuttra |
| Sanofi-Aventis U.S. LLC | $64.61 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $62.24 | 2022-2023 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $59.46 | 2022-2024 | Farxiga |
| Genzyme Corporation | $49.72 | 2025 | |
| Scpharmaceuticals INC. | $43.18 | 2025 | |
| Novartis Pharmaceuticals Corporation | $35.30 | 2024 | |
| Alexion Pharmaceuticals, INC. | $25.36 | 2022 | |
| Vital Connect, INC | $20.00 | 2024 | Vitalpatch Rtm |
| Kiniksa Pharmaceuticals, LTD. | $17.16 | 2023 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $16.58 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Platzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.